Is all of the upside already baked into Medivation?
In this video segment, Motley Fool health care bureau chief Brenton Flynn looks at Medivation (MDVN). Shares already have a lot of high expectations priced in, and the company's prostate cancer drug Xtadi sells at a 30% premium compared to competitor Zytiga from Johnson & Johnson. With similar efficacy, what will Medivation need to do to help justify the premium pricing of both its drug and stock?
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
